α,α-dichlorocyclobutanone | 63329-89-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: α,α-dichlorocyclobutanone
• 英文别名: 2,2-dichlorocyclobutanone；dichlorocyclobutanone；dichlorocyclobutanon；2,2-Dichlorocyclobutan-1-one
• CAS: 63329-89-5
• 化学式: C₄H₄Cl₂O
• 分子量: 138.981
• InChiKey: QXUHNJCSRRDWIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  206.9±40.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  α,α-dichlorocyclobutanone 在 锌 作用下， 以 溶剂黄146 为溶剂， 生成 环丁酮
  参考文献：
  名称：

  硫酰氟 (SO2F2) 介导的环丁酮肟合成脂肪腈

  摘要：

  摘要 开发了SO 2 F 2介导的环丁酮肟衍生物与烯烃的开环交叉偶联，用于构建一系列具有( E )构型选择性的含δ-烯烃的脂肪腈。这种新方法具有底物范围广、条件温和、直接N-O活化等特点。 贝尔斯坦 J. 组织。化学。 2023, 19, 901–908。doi:10.3762/bjoc.19.68

  DOI：

  10.3762/bjoc.19.68
• 作为产物：
  描述：

  乙烯 、 三氯乙酰氯 在 锌铜偶 、 三氯氧磷 作用下， 以 乙醚 为溶剂， 生成 α,α-dichlorocyclobutanone
  参考文献：
  名称：

  铜催化串联需氧氧化环化为4- cyanoalkylpyrrolo [1,2的合成一个]喹喔啉，从1-（2-氨基苯基）吡咯和环丁酮肟酯†

  摘要：

  已开发了一种铜催化串联开环/环化反应，用于由1-（2-氨基苯基）吡咯和环丁酮肟酯合成4-氰基烷基吡咯并[1,2- a ]喹喔啉。该反应涉及C–C键断裂以及具有良好官能团耐受性的C–C和C–N键结构。在温和的条件下，可以以中等到良好的产率获得各种各样的产品。

  DOI：

  10.1039/c8cc06256k

文献信息

• Synthesis of trisubstituted alkenes by Ni-catalyzed hydroalkylation of internal alkynes with cycloketone oxime esters
  作者：Xiao-Yu Lu、Chuang-Chuang Liu、Run-Chuang Jiang、Lu-Yu Yan、Qi-Le liu、Qing-Qing Wang、Jia-Mei Li

  DOI：10.1039/d0cc06517j

  日期：——

  Ni-catalyzed hydroalkylation of internal alkynes with cycloketone oxime esters was developed. The reaction has a broad substrate scope. This hydroalkylation shows excellent regio- and stereo-selectivity. This method enables readily available starting materials to be used to access a range of cyano-substituted single-configuration trisubstituted alkenes. These are valuable feedstock chemicals and are widely

  提出了一种用环酮肟酯对内炔烃进行Ni催化加氢烷基化的方法。该反应具有广泛的底物范围。这种加氢烷基化显示出优异的区域选择性和立体选择性。该方法使得容易获得的起始原料可用于获得一定范围的氰基取代的单构型三取代的烯烃。这些是有价值的原料化学品，并广泛用于合成和药物化学中。
• [EN] AMPHIPHILIC CYCLOBUTENES AND CYCLOBUTANES<br/>[FR] CYCLOBUTÈNES ET CYCLOBUTANES AMPHIPHILES
  申请人：NUTECH VENTURES

  公开号：WO2013181155A1

  公开（公告）日：2013-12-05

  This disclosure relates to amphiphilic compounds containing a cyclobutene or cyclobutane moiety. In some embodiments, the compounds are useful for treating infection by Mycobacterium such as Mycobacterium tuberculosis. Cyclobutene containing compounds are also useful as monomers in the preparation of amphiphilic polymers.

  这项披露涉及含有环丁烯或环丁烷基团的两性化合物。在某些实施例中，这些化合物可用于治疗结核分枝杆菌等分枝杆菌感染。含环丁烯的化合物还可用作两性聚合物的单体。
• Novel FXR (NR1H4) binding and activity modulating compounds
  申请人：Phenex Pharmaceuticals AG

  公开号：EP2545964A1

  公开（公告）日：2013-01-16

  The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds. wherein R is selected from the group consisting of COOR6, CONR7R8, tetrazolyl, SO2NR7R8, C1-6 alkyl, SO2-C1-6 alkyl and H, with R6 independently selected from the group consisting of H or C1-6 alkyl, and R7 and R8 independently from each other selected from the group consisting of H, C1-6 alkyl, halo-C1-6 alkyl, C1-6 alkylene-R9, SO2-C1-6 alkyl, wherein R9 is selected from the group consisting of COOH, OH and SO3H; A is selected from the group consisting of phenyl, pyridyl, pyrimidyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, oxadiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, O-C1-6 alkyl, O-halo-C1-6 alkyl, C1-6 alkyl, halo-C1-6 alkyl, C3-6 cycloalkyl and halogen; Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6 alkyl, halo-C1-6 alkyl, halogen and CF3; Y is selected from N or CH; Z is selected from wherein X= CH, N, NO.

  本发明涉及与NR1H4受体（FXR）结合并作为NR1H4受体（FXR）激动剂的化合物。该发明还涉及利用这些化合物制备用于治疗疾病和/或病况的药物，通过这些化合物结合所述核受体来实现，并涉及一种合成这些化合物的方法。其中R从COOR6，CONR7R8，四唑基，SO2NR7R8，C1-6烷基，SO2-C1-6烷基和H组成的群体中选择，R6独立地从H或C1-6烷基组成的群体中选择，R7和R8相互独立地从H，C1-6烷基，卤代C1-6烷基，C1-6烷基烯基-R9，SO2-C1-6烷基中选择，其中R9从COOH，OH和SO3H组成的群体中选择；A从苯基，吡啶基，嘧啶基，吡唑基，吲哚基，噻吩基，苯并噻吩基，吲哚啉基，苯并异噁唑基，苯并呋喃基，苯并三唑基，呋喃基，苯并噻唑基，噻唑基，氧代二唑基中选择，每种基可选择地被一个或两个基独立地从OH，O-C1-6烷基，O-卤代C1-6烷基，C1-6烷基，卤代C1-6烷基，C3-6环烷基和卤素取代；Q从苯基，吡啶基，噻唑基，噻吩基，嘧啶基中选择，每种基可选择地被一个或两个基独立地从C1-6烷基，卤代C1-6烷基，卤素和CF3中选择；Y从N或CH中选择；Z从中选择其中X= CH，N，NO。
• NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS
  申请人：Kinzel Olaf

  公开号：US20140221659A1

  公开（公告）日：2014-08-07

  The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本发明涉及结合NR1H4受体（FXR）并作为FXR激动剂的化合物。该发明还涉及利用这些化合物制备药物以治疗疾病和/或病况，通过这些化合物结合所述核受体，并涉及这些化合物的合成过程。
• Phthalazine compounds and therapeutic agents for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US20030105074A1

  公开（公告）日：2003-06-05

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: 1 wherein R 1 and R 2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R 1 is a chlorine atom, R 2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种治疗勃起功能障碍的邻苯二氮杂环化合物，其化学式如下，其药理学上可接受的盐或水合物：1其中，R1和R2相同或不同，表示卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X表示氰基、硝基、卤素原子、可能被取代的羟肟基或可能被取代的杂环基；Y表示杂环基、可能被取代的芳基、可能被取代的炔基、烯基、烷基、可选取代的饱和或不饱和4-至8环胺环，所述的环胺化合物是单环化合物、双环化合物或螺环化合物；l是1到3的整数；但当l为1或2时，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基，Y为取代有羟基的5-或6环胺环时，不在此范围内。